Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 24, Issue 15, Pages -Publisher
MDPI
DOI: 10.3390/ijms241512478
Keywords
breast cancer; breast surgery; early-stage TNBC; immunotherapy; neoadjuvant chemotherapy; PARP inhibitors; triple-negative breast cancer; targeted therapy
Ask authors/readers for more resources
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with heterogeneous characteristics. Neoadjuvant therapy (NAT) is the preferred treatment for early-stage TNBC as it downstages tumors, monitors treatment response, and provides important prognostic information. The use of immune checkpoint inhibitors and targeted agents has revolutionized TNBC treatment, but identifying the subgroups that benefit most from these therapies is still under investigation.
Triple-negative breast cancer (TNBC) is a subtype of breast cancer with both inter- and intratumor heterogeneity, thought to result in a more aggressive course and worse outcomes. Neoadjuvant therapy (NAT) has become the preferred treatment modality of early-stage TNBC as it allows for the downstaging of tumors in the breast and axilla, monitoring early treatment response, and most importantly, provides important prognostic information that is essential to determining post-surgical therapies to improve outcomes. It focuses on combinations of systemic drugs to optimize pathologic complete response (pCR). Excellent response to NAT has allowed surgical de-escalation in ideal candidates. Further, treatment algorithms guide the systemic management of patients based on their pCR status following surgery. The expanding knowledge of molecular pathways, genomic sequencing, and the immunological profile of TNBC has led to the use of immune checkpoint inhibitors and targeted agents, including PARP inhibitors, further revolutionizing the therapeutic landscape of this clinical entity. However, subgroups most likely to benefit from these novel approaches in TNBC remain elusive and are being extensively studied. In this review, we describe current practices and promising therapeutic options on the horizon for TNBC, surgical advances, and future trends in molecular determinants of response to therapy in early-stage TNBC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available